Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Inventory: 2013-2024

Historic Inventory for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $153.7 million.

  • Amphastar Pharmaceuticals' Inventory rose 42.68% to $185.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.9 million, marking a year-over-year increase of 42.68%. This contributed to the annual value of $153.7 million for FY2024, which is 45.27% up from last year.
  • According to the latest figures from FY2024, Amphastar Pharmaceuticals' Inventory is $153.7 million, which was up 45.27% from $105.8 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Inventory peaked at $153.7 million during FY2024, and registered a low of $92.8 million during FY2021.
  • Moreover, its 3-year median value for Inventory was $105.8 million (2023), whereas its average is $121.1 million.
  • Its Inventory has fluctuated over the past 5 years, first fell by 12.37% in 2020, then surged by 45.27% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Inventory (Yearly) stood at $96.8 million in 2020, then decreased by 4.16% to $92.8 million in 2021, then climbed by 11.61% to $103.6 million in 2022, then increased by 2.17% to $105.8 million in 2023, then soared by 45.27% to $153.7 million in 2024.